Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori
Sponsor: Reham Abdelkader Elkhouly
Summary
The primary objective of the study is to compare the efficacy of 2 different regimens of treatment of gastric bacteria (H pylori) these are: quadruple bismuth therapy and clarithromycin triple therapy with add-on bismuth, in eradicating H. pylori. The secondary objective of the study is detection of adverse effects and treatment compliance in both regimens.
Official title: Eradication of Helicobacter Pylori: A Comparative Randomized Controlled Trial of Bismuth Quadruple Therapy and Bismuth Add-on to Clarithromycin Triple Therapy
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2023-09-01
Completion Date
2025-09-01
Last Updated
2026-09-11
Healthy Volunteers
No
Conditions
Interventions
Bismuth added on triple therapy
A 14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Clarithromycin (500 mg twice daily), Amoxicillin (1 g twice daily), and the proton pump inhibitor (PPI) Esomeprazole (40 mg twice daily).
Quadruple therapy
14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Doxycycline (100 mg twice daily), Metronidazole (500 mg three times daily), and Esomeprazole (40 mg twice daily).
Locations (1)
Tanta university
Tanta, Algharbia, Egypt